Liquid profiling for cancer patient stratification in precision medicine: current status and challenges for successful implementation in standard care

Circulating tumor DNA (ctDNA), accurately described by the term liquid profiling (LP), enables real-time assessment of the tumor mutational profile as a minimally invasive test and has therefore rapidly gained traction, particular for the management of cancer patients. By LP, tumor-specific genetic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Haselmann, Verena (VerfasserIn) , Hedtke, Maren (VerfasserIn) , Neumaier, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: July 4, 2022
In: Journal of laboratory medicine
Year: 2022, Jahrgang: 46, Heft: 4, Pages: 225-236
ISSN:2567-9449
DOI:10.1515/labmed-2022-0066
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1515/labmed-2022-0066
Verlag, lizenzpflichtig, Volltext: https://www.degruyterbrill.com/document/doi/10.1515/labmed-2022-0066/html
Volltext
Verfasserangaben:Verena Haselmann, Maren Hedtke and Michael Neumaier

MARC

LEADER 00000caa a2200000 c 4500
001 1826722998
003 DE-627
005 20250530003524.0
007 cr uuu---uuuuu
008 221209s2022 xx |||||o 00| ||eng c
024 7 |a 10.1515/labmed-2022-0066  |2 doi 
035 |a (DE-627)1826722998 
035 |a (DE-599)KXP1826722998 
035 |a (OCoLC)1361670138 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 30  |2 sdnb 
100 1 |a Haselmann, Verena  |d 1982-  |e VerfasserIn  |0 (DE-588)1153803097  |0 (DE-627)1015321275  |0 (DE-576)500568154  |4 aut 
245 1 0 |a Liquid profiling for cancer patient stratification in precision medicine  |b current status and challenges for successful implementation in standard care  |c Verena Haselmann, Maren Hedtke and Michael Neumaier 
264 1 |c July 4, 2022 
300 |b Illustrationen 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 09.12.2022 
520 |a Circulating tumor DNA (ctDNA), accurately described by the term liquid profiling (LP), enables real-time assessment of the tumor mutational profile as a minimally invasive test and has therefore rapidly gained traction, particular for the management of cancer patients. By LP, tumor-specific genetic alterations can be determined as part of companion diagnostics to guide selection of appropriate targeted therapeutics. Because LP facilitates longitudinal monitoring of cancer patients, it can be used to detect acquired resistant mechanisms or as a personalized biomarker for earlier detection of disease recurrence, among other applications. However, LP is not yet integrated into routine care to the extent that might be expected. This is due to the lack of harmonization and standardization of preanalytical and analytical workflows, the lack of proper quality controls, limited evidence of its clinical utility, heterogenous study results, the uncertainty of clinicians regarding the value and appropriate indications for LP and its interpretation, and finally, the lack of reimbursement for most LP tests. In this review, the value proposition of LP for cancer patient management and treatment optimization, the current status of implementation in standard care, and the main challenges that need to be overcome are discussed in detail. 
650 4 |a cancer management 
650 4 |a cell-free DNA 
650 4 |a circulating tumor DNA 
650 4 |a clinical oncology 
650 4 |a liquid biopsy 
650 4 |a liquid profiling 
650 4 |a personalized medicine 
650 4 |a standard care 
700 1 |a Hedtke, Maren  |d 1983-  |e VerfasserIn  |0 (DE-588)102962755X  |0 (DE-627)734325169  |0 (DE-576)377492418  |4 aut 
700 1 |a Neumaier, Michael  |d 1958-  |e VerfasserIn  |0 (DE-588)1028284934  |0 (DE-627)730532623  |0 (DE-576)375780580  |4 aut 
773 0 8 |i Enthalten in  |t Journal of laboratory medicine  |d Berlin : De Gruyter, 2018  |g 46(2022), 4 vom: Juli, Seite 225-236  |w (DE-627)1000979482  |w (DE-600)2909042-8  |w (DE-576)494601744  |x 2567-9449  |7 nnas  |a Liquid profiling for cancer patient stratification in precision medicine current status and challenges for successful implementation in standard care 
773 1 8 |g volume:46  |g year:2022  |g number:4  |g month:07  |g pages:225-236  |g extent:12  |a Liquid profiling for cancer patient stratification in precision medicine current status and challenges for successful implementation in standard care 
856 4 0 |u https://doi.org/10.1515/labmed-2022-0066  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.degruyterbrill.com/document/doi/10.1515/labmed-2022-0066/html  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20221209 
993 |a Article 
994 |a 2022 
998 |g 1028284934  |a Neumaier, Michael  |m 1028284934:Neumaier, Michael  |d 60000  |d 63300  |e 60000PN1028284934  |e 63300PN1028284934  |k 0/60000/  |k 1/60000/63300/  |p 3  |y j 
998 |g 102962755X  |a Hedtke, Maren  |m 102962755X:Hedtke, Maren  |d 60000  |e 60000PH102962755X  |k 0/60000/  |p 2 
998 |g 1153803097  |a Haselmann, Verena  |m 1153803097:Haselmann, Verena  |d 60000  |e 60000PH1153803097  |k 0/60000/  |p 1  |x j 
999 |a KXP-PPN1826722998  |e 4228743447 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"given":"Verena","role":"aut","family":"Haselmann","display":"Haselmann, Verena"},{"display":"Hedtke, Maren","family":"Hedtke","given":"Maren","role":"aut"},{"family":"Neumaier","display":"Neumaier, Michael","role":"aut","given":"Michael"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Liquid profiling for cancer patient stratification in precision medicine","subtitle":"current status and challenges for successful implementation in standard care","title_sort":"Liquid profiling for cancer patient stratification in precision medicine"}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"July 4, 2022"}],"note":["Gesehen am 09.12.2022"],"id":{"eki":["1826722998"],"doi":["10.1515/labmed-2022-0066"]},"physDesc":[{"extent":"12 S.","noteIll":"Illustrationen"}],"name":{"displayForm":["Verena Haselmann, Maren Hedtke and Michael Neumaier"]},"relHost":[{"part":{"pages":"225-236","year":"2022","issue":"4","text":"46(2022), 4 vom: Juli, Seite 225-236","extent":"12","volume":"46"},"language":["eng"],"corporate":[{"display":"Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin","role":"isb"}],"id":{"zdb":["2909042-8"],"issn":["2567-9449"],"eki":["1000979482"]},"recId":"1000979482","disp":"Liquid profiling for cancer patient stratification in precision medicine current status and challenges for successful implementation in standard careJournal of laboratory medicine","type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Journal of laboratory medicine","title_sort":"Journal of laboratory medicine","subtitle":"official journal of the German Society of Clinical Chemistry and Laboratory Medicine"}],"note":["Gesehen am 07.10.24"],"pubHistory":["Volume 42, issue 1/2 (2018)-"],"origin":[{"publisherPlace":"Berlin","dateIssuedDisp":"2018-","publisher":"De Gruyter","dateIssuedKey":"2018"}]}],"recId":"1826722998"} 
SRT |a HASELMANNVLIQUIDPROF4202